UA105405C2 - Гуманизированное антитело против человеческого il-22ra - Google Patents
Гуманизированное антитело против человеческого il-22raInfo
- Publication number
- UA105405C2 UA105405C2 UAA201207335A UAA201207335A UA105405C2 UA 105405 C2 UA105405 C2 UA 105405C2 UA A201207335 A UAA201207335 A UA A201207335A UA A201207335 A UAA201207335 A UA A201207335A UA 105405 C2 UA105405 C2 UA 105405C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- humanized anti
- psoriasis
- immune
- treatment
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09176525 | 2009-11-19 | ||
| PCT/EP2010/067332 WO2011061119A1 (en) | 2009-11-19 | 2010-11-12 | Humanized antibodies against human il-22ra |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA105405C2 true UA105405C2 (ru) | 2014-05-12 |
Family
ID=41565648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201207335A UA105405C2 (ru) | 2009-11-19 | 2010-11-12 | Гуманизированное антитело против человеческого il-22ra |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8545844B2 (enExample) |
| EP (1) | EP2512511B1 (enExample) |
| JP (1) | JP5818804B2 (enExample) |
| KR (1) | KR20120098783A (enExample) |
| CN (1) | CN102665759B (enExample) |
| AU (1) | AU2010321047B2 (enExample) |
| BR (1) | BR112012012003A2 (enExample) |
| CA (1) | CA2778864C (enExample) |
| EA (1) | EA021356B1 (enExample) |
| EC (1) | ECSP12011980A (enExample) |
| ES (1) | ES2531996T3 (enExample) |
| IL (1) | IL219740A0 (enExample) |
| IN (1) | IN2012DN03362A (enExample) |
| MX (1) | MX2012005791A (enExample) |
| NZ (1) | NZ599438A (enExample) |
| PE (1) | PE20121560A1 (enExample) |
| PH (1) | PH12012500924A1 (enExample) |
| UA (1) | UA105405C2 (enExample) |
| WO (1) | WO2011061119A1 (enExample) |
| ZA (1) | ZA201202793B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007004770A (es) * | 2004-10-22 | 2007-11-22 | Zymogenetics Inc | Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion. |
| HUE039849T2 (hu) | 2011-03-16 | 2019-02-28 | Argenx Bvba | CD70 elleni ellenanyagok |
| CN107318267B (zh) | 2013-08-12 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于治疗补体相关的病症的组合物和方法 |
| PE20161440A1 (es) * | 2014-05-01 | 2017-01-26 | Genentech Inc | Variantes del anticuerpo anti-factor d y sus usos |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
| JP2018536650A (ja) | 2015-10-30 | 2018-12-13 | ジェネンテック， インコーポレイテッド | 抗ｄ因子抗体変異体コンジュゲート及びその使用 |
| ES2966133T3 (es) * | 2016-03-18 | 2024-04-18 | Staidson Beijing Biopharmaceuticals Co Ltd | Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma |
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
| EP3630182A4 (en) * | 2017-05-24 | 2021-02-24 | Development Center for Biotechnology | HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT |
| KR102611853B1 (ko) | 2017-06-30 | 2023-12-08 | 자임워크스 비씨 인코포레이티드 | 안정화된 키메라 fabs |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| WO2023232789A1 (en) * | 2022-06-03 | 2023-12-07 | Leo Pharma A/S | Liquid formulation of il-22r antibody |
| WO2024184333A1 (en) | 2023-03-08 | 2024-09-12 | Leo Pharma A/S | Il-22r antibody for use in treating atopic dermatitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
| MX2007004770A (es) * | 2004-10-22 | 2007-11-22 | Zymogenetics Inc | Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion. |
| KR20070114324A (ko) * | 2005-03-25 | 2007-11-30 | 글리카트 바이오테크놀로지 아게 | Ｍｃｓｐ 에 향하며 증가된 ｆｃ 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자 |
| CA2631961A1 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22 |
-
2010
- 2010-11-12 IN IN3362DEN2012 patent/IN2012DN03362A/en unknown
- 2010-11-12 NZ NZ599438A patent/NZ599438A/en not_active IP Right Cessation
- 2010-11-12 MX MX2012005791A patent/MX2012005791A/es active IP Right Grant
- 2010-11-12 ES ES10779768.0T patent/ES2531996T3/es active Active
- 2010-11-12 BR BR112012012003A patent/BR112012012003A2/pt not_active IP Right Cessation
- 2010-11-12 KR KR1020127015390A patent/KR20120098783A/ko not_active Withdrawn
- 2010-11-12 CN CN201080052724.0A patent/CN102665759B/zh not_active Expired - Fee Related
- 2010-11-12 AU AU2010321047A patent/AU2010321047B2/en not_active Ceased
- 2010-11-12 EP EP10779768.0A patent/EP2512511B1/en active Active
- 2010-11-12 PE PE2012000669A patent/PE20121560A1/es not_active Application Discontinuation
- 2010-11-12 EA EA201290360A patent/EA021356B1/ru not_active IP Right Cessation
- 2010-11-12 PH PH1/2012/500924A patent/PH12012500924A1/en unknown
- 2010-11-12 US US13/510,068 patent/US8545844B2/en not_active Expired - Fee Related
- 2010-11-12 WO PCT/EP2010/067332 patent/WO2011061119A1/en not_active Ceased
- 2010-11-12 CA CA2778864A patent/CA2778864C/en not_active Expired - Fee Related
- 2010-11-12 JP JP2012539274A patent/JP5818804B2/ja not_active Expired - Fee Related
- 2010-11-12 UA UAA201207335A patent/UA105405C2/ru unknown
-
2012
- 2012-04-17 ZA ZA2012/02793A patent/ZA201202793B/en unknown
- 2012-05-13 IL IL219740A patent/IL219740A0/en unknown
- 2012-06-18 EC ECSP12011980 patent/ECSP12011980A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012012003A2 (pt) | 2016-11-29 |
| ES2531996T3 (es) | 2015-03-23 |
| EP2512511B1 (en) | 2015-01-07 |
| EA021356B1 (ru) | 2015-05-29 |
| CA2778864A1 (en) | 2011-05-26 |
| ECSP12011980A (es) | 2012-07-31 |
| CN102665759B (zh) | 2015-09-30 |
| MX2012005791A (es) | 2012-07-03 |
| ZA201202793B (en) | 2013-06-26 |
| IN2012DN03362A (enExample) | 2015-10-23 |
| CA2778864C (en) | 2017-06-27 |
| AU2010321047A1 (en) | 2012-05-24 |
| WO2011061119A1 (en) | 2011-05-26 |
| PE20121560A1 (es) | 2012-12-05 |
| AU2010321047B2 (en) | 2016-06-09 |
| NZ599438A (en) | 2013-12-20 |
| PH12012500924A1 (en) | 2012-11-26 |
| EA201290360A1 (ru) | 2012-11-30 |
| CN102665759A (zh) | 2012-09-12 |
| JP2013511267A (ja) | 2013-04-04 |
| US20120230990A1 (en) | 2012-09-13 |
| KR20120098783A (ko) | 2012-09-05 |
| US8545844B2 (en) | 2013-10-01 |
| IL219740A0 (en) | 2012-07-31 |
| JP5818804B2 (ja) | 2015-11-18 |
| EP2512511A1 (en) | 2012-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA105405C2 (ru) | Гуманизированное антитело против человеческого il-22ra | |
| CY1120413T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
| EA201291039A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
| UA109658C2 (xx) | Антитіло проти cgrp | |
| EA201390493A1 (ru) | Человеческие антитела к онкостатину м и способы их применения | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| JO3097B1 (ar) | الأجسام المضادة c-Met | |
| UA104626C2 (ru) | Анти-vegf антитело и его применение | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| EA201101530A1 (ru) | ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ | |
| NZ599737A (en) | Il-17a antagonists | |
| MX359794B (es) | Anticuerpos anti-hepcidina y usos de los mismos. | |
| CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
| UA103916C2 (xx) | Антитіло проти dkk-1$антитело против dkk-1 | |
| EA201300819A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f | |
| EA201590402A1 (ru) | ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| GB201109238D0 (en) | Antibodies | |
| EA201591133A1 (ru) | СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19 | |
| MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
| CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
| MX2023004315A (es) | Anticuerpo neutralizante que se une a il-17a humana y a il-17f humana para usarse en el tratamiento de artritis. | |
| EA201891594A1 (ru) | Антитела к il-17c | |
| BR112013023513A2 (pt) | anticorpos que ligam tgf-alfa e epiregulina |